A new generation of flu vaccines
The results of clinical trials of the first Russian tetravalent vaccine for the prevention of influenza are presented at the Sixth ESWI Influenza Conference
NPO Petrovax Pharm presented the results of clinical trials of the first Russian tetravalent vaccine for the prevention of influenza at the Sixth ESWI Influenza Conference, held in Riga on September 10-13, 2017.
The Sixth ESWI Influenza Conference is the largest European scientific conference on influenza, organized by the European Scientific Working Group on Influenza, which is held every three years. The international congress is attended by well-known scientists and leading experts in the field of influenza and vaccine prevention from all over the world. This year's conference addressed topical issues of influenza, new threats and pandemics, provided an overview of recent developments in the field of epidemiological surveillance and vaccination, presented achievements and prospects in the fight against a dangerous disease.
NPO Petrovax Pharm, along with the world's leading manufacturers of vaccines and antiviral drugs, took an active part in the conference. On September 12, Marina Abramova, Vice President for Development, Research and Implementation of Drugs at Petrovax Pharm NGO, presented the results of clinical trials of the first Russian quadrivalent influenza vaccine, Grippol® Quadrivalent, as part of the scientific symposium "A new generation of influenza vaccines: the future of influenza vaccination", and also told about the history of the creation and use of inactivated subunit adjuvant vaccines of the Grippol® group.
"Grippol® Quadrivalent is the most modern vaccine of the existing influenza vaccines in the world with high preventive efficacy and safety, which protects against four strains of the influenza virus at once," Marina Abramova noted. - The vaccine contains the immunoadjuvant Polyoxidonium, which contributes to the development of a stable immune response and provides a high safety profile. The vaccine will be produced in Russia using full-cycle technology, starting from the stage of release of substances. Clinical studies in adults have been successfully completed, their results have confirmed the efficacy and safety of Grippol® Quadrivalent and compliance with the international criteria of EMA CPMP," she stressed Marina Abramova. Currently, documents for state registration have been submitted to the Ministry of Health of the Russian Federation. In 2018, the vaccine will be introduced to the Russian market. Possible production volumes will amount to 40 million doses annually.
Since 2012, WHO has been giving recommendations on vaccination with quadrivalent influenza vaccines. Only five countries in the world have the production of quadrivalent vaccines: Australia, USA, Canada, Germany and France. Russia will be the sixth country in the world to have its own independent production of such vaccines.
Portal "Eternal youth" http://vechnayamolodost.ru
14.09.2017